A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Trial Profile

A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs ISC-hpNSC (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors Cyto Therapeutics
  • Most Recent Events

    • 29 Nov 2017 According to an International Stem Cell Corporation media release, 7th Patient (a third patient of the second cohort) with Parkinson's disease was successfully transplanted with ISCO's proprietary ISC-hpNSC cells.
    • 13 Nov 2017 Six months interim results of the first cohort of Parkinson's disease (PD) patients receiving 30 million ISC-hpNSC cells published in an International Stem Cell Corporation media release.
    • 08 Nov 2017 According to an International Stem Cell Corporation media release, the company will present six-month's results at the Society for Neurosciences 47th annual meeting, Neuroscience 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top